Il Yang to obtain KFDA approval on anti-cancer bulk drug.

Published: 2005-10-31 06:59:00

Updated: 2005-10-31 06:59:00

Il Yang has obtained the KFDA approval for the manufacturing licence of an anti-cancer bulk drug, which was developed from an organism of mushroom called Phellinus linteus for the enhancement of immunity against various GI cancers such as stomach, esophagus, duodenal, sigmoid, rectal and colon ca...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK